Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Dec;90(3):363–367. doi: 10.1111/j.1365-2249.1992.tb05852.x

Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha.

H Gisslinger 1, B Gilly 1, W Woloszczuk 1, W R Mayr 1, L Havelec 1, W Linkesch 1, M Weissel 1
PMCID: PMC1554585  PMID: 1458673

Abstract

Forty-five patients with myeloproliferative or myelodysplastic syndromes, treated with recombinant interferon-alpha (rIFN-alpha) for a minimum of 1 up to 4 years, were examined for the occurrence of thyroid autoimmunity. During treatment, the rate of thyroid autoimmunity rose to more than 20%. The decrease in severity and frequency of thyroid autoimmunity after withdrawal of IFN shows that this is a potentially reversible side effect. The key determinant for the manifestation of this IFN-related autoimmune phenomenon seems to be a predisposition for autoimmunity, since patients with initially detectable thyroid antibodies are prone to exacerbations of thyroid autoimmunity. Concurrent with thyroid autoimmunity, hypothyroidism occurred but did not correlate with the levels of thyroid antibodies, although severe hypothyroidism in two patients was accompanied by increased levels of thyroid antibodies. This investigation shows that thyroid autoimmunity and consecutively hypothyroidism must be expected in certain patients treated with rIFN-alpha during long periods. Furthermore, it may be assumed that IFN-alpha does not induce the development of autoimmunity, but rather enhances the levels of pre-existent thyroid antibodies.

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkins M. B., Mier J. W., Parkinson D. R., Gould J. A., Berkman E. M., Kaplan M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988 Jun 16;318(24):1557–1563. doi: 10.1056/NEJM198806163182401. [DOI] [PubMed] [Google Scholar]
  2. Beever K., Bradbury J., Phillips D., McLachlan S. M., Pegg C., Goral A., Overbeck W., Feifel G., Smith B. R. Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem. 1989 Sep;35(9):1949–1954. [PubMed] [Google Scholar]
  3. Burman P., Tötterman T. H., Oberg K., Karlsson F. A. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 1986 Nov;63(5):1086–1090. doi: 10.1210/jcem-63-5-1086. [DOI] [PubMed] [Google Scholar]
  4. Conlon K. C., Urba W. J., Smith J. W., 2nd, Steis R. G., Longo D. L., Clark J. W. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990 May 15;65(10):2237–2242. doi: 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  5. Daniels H. M., Meager A., Eddleston A. L., Alexander G. J., Williams R. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet. 1990 Apr 14;335(8694):875–877. doi: 10.1016/0140-6736(90)90475-k. [DOI] [PubMed] [Google Scholar]
  6. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  7. Fentiman I. S., Balkwill F. R., Thomas B. S., Russell M. J., Todd I., Bottazzo G. F. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1299–1303. doi: 10.1016/0277-5379(88)90219-2. [DOI] [PubMed] [Google Scholar]
  8. Gisslinger H., Chott A., Linkesch W., Fritz E., Ludwig H. Long-term alpha-interferon therapy in myelodysplastic syndromes. Leukemia. 1990 Feb;4(2):91–94. [PubMed] [Google Scholar]
  9. Gisslinger H., Chott A., Scheithauer W., Gilly B., Linkesch W., Ludwig H. Interferon in essential thrombocythaemia. Br J Haematol. 1991 Oct;79 (Suppl 1):42–47. doi: 10.1111/j.1365-2141.1991.tb08118.x. [DOI] [PubMed] [Google Scholar]
  10. Gisslinger H., Ludwig H., Linkesch W., Chott A., Fritz E., Radaszkiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989 Mar 25;1(8639):634–637. doi: 10.1016/s0140-6736(89)92142-9. [DOI] [PubMed] [Google Scholar]
  11. Hoekman K., von Blomberg-van der Flier B. M., Wagstaff J., Drexhage H. A., Pinedo H. M. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet. 1991 Aug 31;338(8766):541–542. doi: 10.1016/0140-6736(91)91103-2. [DOI] [PubMed] [Google Scholar]
  12. Huber C., Batchelor J. R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984 Jul 1;160(1):310–316. doi: 10.1084/jem.160.1.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lucas-Martin A., Foz-Sala M., Todd I., Bottazzo G. F., Pujol-Borrell R. Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid diseases: relationship with lymphocytic infiltration and thyroid autoantibodies. J Clin Endocrinol Metab. 1988 Feb;66(2):367–375. doi: 10.1210/jcem-66-2-367. [DOI] [PubMed] [Google Scholar]
  14. Mayet W. J., Hess G., Gerken G., Rossol S., Voth R., Manns M., Meyer zum Büschenfelde K. H. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 1989 Jul;10(1):24–28. doi: 10.1002/hep.1840100106. [DOI] [PubMed] [Google Scholar]
  15. Mufti G. J., Figes A., Hamblin T. J., Oscier D. G., Copplestone J. A. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986 May;63(1):143–147. doi: 10.1111/j.1365-2141.1986.tb07504.x. [DOI] [PubMed] [Google Scholar]
  16. Phillips D., Prentice L., Upadhyaya M., Lunt P., Chamberlain S., Roberts D. F., McLachlan S., Smith B. R. Autosomal dominant inheritance of autoantibodies to thyroid peroxidase and thyroglobulin--studies in families not selected for autoimmune thyroid disease. J Clin Endocrinol Metab. 1991 May;72(5):973–975. doi: 10.1210/jcem-72-5-973. [DOI] [PubMed] [Google Scholar]
  17. Quesada J. R., Hersh E. M., Manning J., Reuben J., Keating M., Schnipper E., Itri L., Gutterman J. U. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986 Aug;68(2):493–497. [PubMed] [Google Scholar]
  18. Quesada J. R., Talpaz M., Rios A., Kurzrock R., Gutterman J. U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986 Feb;4(2):234–243. doi: 10.1200/JCO.1986.4.2.234. [DOI] [PubMed] [Google Scholar]
  19. Rönnblom L. E., Alm G. V., Oberg K. E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991 Aug 1;115(3):178–183. doi: 10.7326/0003-4819-115-3-178. [DOI] [PubMed] [Google Scholar]
  20. Talpaz M., Kantarjian H. M., McCredie K. B., Keating M. J., Trujillo J., Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987 May;69(5):1280–1288. [PubMed] [Google Scholar]
  21. Tandon N., Zhang L., Weetman A. P. HLA associations with Hashimoto's thyroiditis. Clin Endocrinol (Oxf) 1991 May;34(5):383–386. doi: 10.1111/j.1365-2265.1991.tb00309.x. [DOI] [PubMed] [Google Scholar]
  22. Weissel M., Höfer R., Zasmeta H., Mayr W. R. HLA-DR and Hashimoto's thyroiditis. Tissue Antigens. 1980 Sep;16(3):256–257. doi: 10.1111/j.1399-0039.1980.tb00302.x. [DOI] [PubMed] [Google Scholar]
  23. van Liessum P. A., de Mulder P. H., Mattijssen E. J., Corstens F. H., Wagener D. J. Hypothyroidism and goitre during interleukin-2 therapy without LAK cells. Lancet. 1989 Jan 28;1(8631):224–224. doi: 10.1016/s0140-6736(89)91244-0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES